pin in left arm injection site; shivering; achiness; headache; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 74-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 14-JAN-2025, the patient received the 2nd dose of Shingrix (intramuscular, left deltoid). On 15-JAN-2025, 1 days after receiving Shingrix, the patient experienced injection site pain (Verbatim: pin in left arm injection site), shivering (Verbatim: shivering), pain (Verbatim: achiness) and headache (Verbatim: headache). The outcome of the injection site pain, shivering, pain and headache were not resolved. It was unknown if the reporter considered the injection site pain, shivering, pain and headache to be related to Shingrix. It was unknown if the company considered the injection site pain, shivering, pain and headache to be related to Shingrix. Linked case(s) involving the same patient: US2022174220 Additional Information: GSK Receipt Date: 15-JAN-2025 Patient received his second Shingrix vaccine on 14-JAN-2025 and experienced symptoms 24 hours later of shivering, achiness, headache and left arm painful. These symptoms were not resolved. For tolerance of first dose refer case US2022174220.; Sender’s Comments: US-GSK-US2022174220:Same patient